The blood collection tubes for liquid biopsy are the type of blood collection tubes used for collection and storage of blood sample for prolonged time. These tubes provide precision, accuracy, speed safety and ease of use during diagnostic procedures such as liquid biopsy.
Biocept, Inc and F . Hoffmann-La Roche Ltd- Notable Market Players in Blood Collection Tubes for Liquid Biopsy Market
A liquid biopsy is a non-invasive, minimally invasive alternative to surgical biopsies that allows doctors to learn a lot about a tumor by taking a blood sample. Cancer DNA traces in the blood can reveal which treatments are most likely to work for a given patient. The development of numerous specialized measurement techniques has resulted from the possibility of circulating cell-free DNA (cfDNA) analysis. Over the last few years, there has been a surge in interest in the (pre-)analytical conditions of the liquid biopsy workflow.
The blood collection tubes for liquid biopsy market majorly consists of the players such as PreAnalytix GmbH; Biocept, Inc.; F. Hoffmann-La Roche Ltd.; STRECK; Norgen Biotek Corp; Exact Sciences Corporation; Greiner AG; MagBio Genomics, Inc.; Zymo Research Corporation; Apostle Sciences.
The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have adopted several inorganic and organic strategies to accelerate their growth and improve their market position.
Below is the list of the growth strategies done by the players operating in the blood collection tubes for liquid biopsy market:
| Year | News |
| Feb-2021 | Biocept, Inc. announced a collaboration with Protean BioDiagnostics Inc. to investigate the ability of Biocept’s Target SelectorTM molecular assay to assess EGFR status in NSCLC patients. |
| Nov-2019 | Biocept announced the availability of its CEE-Sure Blood Collection Tube and CEE-Sure Sample Collection Shipping Kit in Europe |
| Oct-2020 | Roche and Atea Pharmaceuticals, Inc. announced a collaboration to manufacture and distribute AT-527 Atea’s investigational oral direct-acting antiviral, to people around the globe. AT-527 acts by blocking the viral RNA polymerase enzyme needed for viral replication and is currently being studied in Phase 2 clinical trial for hospitalized patients with moderate COVID-19 |
| Dec-2019 | Roche and Spark Therapeutics, Inc announced the completion of the acquisition following the receipt of regulatory approval from all government authorities required by the merger agreement. This acquisition will improve lives of patients through innovative gene therapies. |
